-
Mashup Score: 1Combined ICI and VEGF Inhibitor Trials in Cancer: Cardiovascular Eligibility Criteria and Adverse Event Reporting - 23 hour(s) ago
A scoping review analyzed the degree to which published phase II to IV trials of combination immune checkpoint inhibitor (ICI) and VEGF inhibitor treatment of cancer reported cardiovascular eligibilit…
Source: ascopost.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1Breast Cancer Survivors: Relationship Satisfaction and Emotional and Physical Well-Being - 1 day(s) ago
Breast cancer survivors’ emotional and physical health may be influenced by the relationship with their partners.
Source: ascopost.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 3Lack of Research Focused on Older Adults With Cancer May Be Contributing to Disparities in Care - 1 day(s) ago
Investigators have found that the current body of research may inadequately address the intersection of aging, health disparities, and cancer outcomes among older patients.
Source: ascopost.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 9
Douglas B. Johnson, MD, MSCI, of Vanderbilt-Ingram Cancer Center, discusses updated guidelines on the use of neoadjuvant therapy, as well as first- and later-line systemic therapies to treat patients with cutaneous melanoma. Wendy Vogel, MSN, FNP, AOCNP, FAPO, of the Advanced Practitioner Society for Hematology and Oncology, summarizes a panel discussion in which she took part, on forming interprofessional oncology care teams that include advanced practitioners. Such collaboration may improve patient
Source: ascopost.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 4
Researchers investigated the risk of T-cell malignant neoplasms and any second primary malignant neoplasms in patients receiving CAR T-cell therapy for hematologic malignancies.
Source: ascopost.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 6
The third prespecified interim analysis of overall survival in the phase III KEYNOTE-564 trial has shown a significant benefit with adjuvant pembrolizumab vs placebo in patients with clear cell renal …
Source: ascopost.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0Treating DCIS: To Escalate or De-escalate? - 2 day(s) ago
There is much debate about the necessity of treating women with ductal carcinoma in situ (DCIS) with surgery or radiotherapy. 1,2 It is disconcerting to many that patients with DCIS are treated in the same way as are women with early-stage invasive breast cancer. Many patients with DCIS have bilateral mastectomies. 2 Much effort is being expended to identify women at sufficiently low risk who might avoid surgery and/or radiotherapy. 3-9 In a recent paper from the UK, Mannu et al followed women with DCIS
Source: ascopost.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1AI Model May Help Predict Treatment Responses, Select Most Effective Cancer Therapies in Patients With Cancer - 2 day(s) ago
Can a novel artificial intelligence (AI) model accurately predict how patients with cancer will respond to certain cancer drugs? A recent study investigated.
Source: ascopost.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 2Advanced-Stage Classical Hodgkin Lymphoma - 3 day(s) ago
Classical Hodgkin lymphoma (HL) is a highly curable disease, but up to 25% of patients will develop relapsed or refractory classical HL. Although most patients achieve complete response following fron…
Source: ascopost.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 8Sophia McKinley, MD, EdM, on Cutaneous Melanoma: Outcomes With Adjuvant Immunotherapy - 3 day(s) ago
Sophia McKinley, MD, EdM, of Massachusetts General Hospital, discusses patterns of recurrence in patients with resected cutaneous melanoma during or after adjuvant immunotherapy. She identifies the risk factors associated with overall survival and treatment failure (Abstract 60). Jenny H. Chang, MD, of the Cleveland Clinic, discusses the current surgical and radiologic treatment paradigm for patients with stage III Merkel cell carcinoma and the potential for neoadjuvant immunotherapy to help manage the
Source: ascopost.comCategories: General Medicine News, Onc News and JournalsTweet
Combined ICI and VEGF Inhibitor Trials in Cancer: Cardiovascular Eligibility Criteria and Adverse Event Reporting https://t.co/3jrqtZJThu #cancer #cardiovascular #cardiooncology #JACCCardioOnc